Purpose

Understanding the mechanisms of how the Type 2 Diabetes medication SGLT2 Inhibitor works on glucose production and induces the breakdown of fatty acids.

Category

IRB Number
20230457HU
NCT Number
-
Open to Enrollment
Yes
Sponsor
-



Study Contact

Principal Investigator
Ralph DeFronzo

Regulatory Point of Contact
Renata Belfort De Aguiar
210-450-3076
belfortda@uthscsa.edu

Regulatory Point of Contact
Andrea Hansis-Diarte
210-567-3208
hansisdiarte@uthscsa.edu

Regulatory Point of Contact
Aurora Merovci
210-567-6691
merovci@uthscsa.edu

Regulatory Point of Contact
Cynthia Ramirez
210-358-7200
ramirezc8@uthscsa.edu



Eligibility

Eligible Ages
-
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

    Type 2 Diabetes between the ages = 30-75 y, BMI = 23-38 kg/m2, HbA1c = 7.0-10%, eGFR > 60 ml/min/1.73m2, BP < 145/85 mmHg.  Participants must be in general good health.  Patients treated with diet, SU, metformin, or SU/MET

Exclusion Criteria

    Patients treated with GLP-1 RA, DPP-4i, TZD, or insulin are excluded